The year of the biotech bull was undoubtedly 2014. Nature Biotechnology has completed a thorough roundup of the runaway successes — and some losers — of the year, in a paper published this week. It’s got a plethora of valuable charts.
Top-grossing biopharmaceuticals
Monoclonal antibody Humira stole the show with $12.5 billion in sales worldwide — half of that hailing from the U.S.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Top IPOs
It seemed as though every other day we had a fresh IPO on our hands. Here are the top 10, in terms of dollars raised:
Top Revenue Gainers & Losers
The year wasn’t quite so fantastic for all biotech players. Arena Pharmaceuticals, for instance, didn’t have the runaway success with its anti-obesity drug Belviq – instead, quite the opposite:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Top Follow-on Offerings
Companies like Receptos and Agios Pharmaceuticals were able to close meaty follow-on rounds, growing their stock value and, in turn, their cash on hand.
